- Home
- SYNA vs GLPG Comparison
SYNA vs GLPG Comparison
Compare SYNA & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYNA
- GLPG
- Stock Information
- Founded
- SYNA 1986
- GLPG 1999
- Country
- SYNA United States
- GLPG Belgium
- Employees
- SYNA N/A
- GLPG N/A
- Industry
- SYNA Computer peripheral equipment
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- SYNA Technology
- GLPG Health Care
- Exchange
- SYNA Nasdaq
- GLPG Nasdaq
- Market Cap
- SYNA 2.5B
- GLPG 2.1B
- IPO Year
- SYNA 2002
- GLPG 2005
- Fundamental
- Price
- SYNA $66.80
- GLPG $32.47
- Analyst Decision
- SYNA Buy
- GLPG Sell
- Analyst Count
- SYNA 8
- GLPG 4
- Target Price
- SYNA $94.29
- GLPG $25.33
- AVG Volume (30 Days)
- SYNA 481.9K
- GLPG 441.1K
- Earning Date
- SYNA 08-07-2025
- GLPG 07-23-2025
- Dividend Yield
- SYNA N/A
- GLPG N/A
- EPS Growth
- SYNA N/A
- GLPG N/A
- EPS
- SYNA N/A
- GLPG N/A
- Revenue
- SYNA $1,074,300,000.00
- GLPG $323,674,692.00
- Revenue This Year
- SYNA $9.47
- GLPG N/A
- Revenue Next Year
- SYNA $10.37
- GLPG N/A
- P/E Ratio
- SYNA N/A
- GLPG N/A
- Revenue Growth
- SYNA 11.98
- GLPG 5.43
- 52 Week Low
- SYNA $41.80
- GLPG $22.36
- 52 Week High
- SYNA $89.81
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- SYNA 54.74
- GLPG 55.82
- Support Level
- SYNA $66.06
- GLPG $31.30
- Resistance Level
- SYNA $69.32
- GLPG $32.91
- Average True Range (ATR)
- SYNA 2.68
- GLPG 0.80
- MACD
- SYNA 0.52
- GLPG -0.23
- Stochastic Oscillator
- SYNA 76.62
- GLPG 45.70
About SYNA Synaptics Incorporated $0.001 Par Value
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. Geographically, it derives a majority of revenue from China. The company operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.